These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28084558)

  • 21. Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease.
    Quiroga B; Muñoz Ramos P; Álvarez Chiva V
    Nefrologia (Engl Ed); 2020; 40(5):499-505. PubMed ID: 32682569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The lipid story in chronic kidney disease: a long story with a happy end?
    Kujawa-Szewieczek A; Więcek A; Piecha G
    Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid management in patients with chronic kidney disease.
    Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
    Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
    Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
    Atherosclerosis; 2016 May; 248():17-26. PubMed ID: 26978583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.
    Garoufi A; Drapanioti S; Marmarinos A; Askiti V; Mitsioni AJ; Mila M; Grigoriadou G; Georgakopoulos D; Stefanidis CJ; Gourgiotis D
    BMC Nephrol; 2017 Mar; 18(1):113. PubMed ID: 28359257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
    Ferri N; Ruscica M
    Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
    Choi HS; Kim CS; Ma SK; Kim SW; Bae EH
    Ann Palliat Med; 2020 Jul; 9(4):2357-2360. PubMed ID: 32648458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dyslipidemia and stroke in patients with chronic kidney disease].
    Kes P; Bašić-Kes V; Furic-Cunko V; Mesar I; Bašić-Jukić N
    Acta Med Croatica; 2014 Apr; 68(2):141-9. PubMed ID: 26012152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyslipidemia in patients with chronic kidney disease.
    Hager MR; Narla AD; Tannock LR
    Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations.
    Gerritsen KG; Abrahams AC; Peters HP; Nguyen TQ; Koeners MP; den Hoedt CH; Dendooven A; van den Dorpel MA; Blankestijn PJ; Wetzels JF; Joles JA; Goldschmeding R; Kok RJ
    Am J Kidney Dis; 2012 May; 59(5):619-27. PubMed ID: 22342213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
    Zuzda K; Grycuk W; Małyszko J; Małyszko J
    Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort.
    Warady BA; Abraham AG; Schwartz GJ; Wong CS; Muñoz A; Betoko A; Mitsnefes M; Kaskel F; Greenbaum LA; Mak RH; Flynn J; Moxey-Mims MM; Furth S
    Am J Kidney Dis; 2015 Jun; 65(6):878-88. PubMed ID: 25799137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases.
    Dufek S; Ylinen E; Trautmann A; Alpay H; Ariceta G; Aufricht C; Bacchetta J; Bakkaloglu S; Bayazit A; Caliskan S; do Sameiro Faria M; Dursun I; Ekim M; Jankauskiene A; Klaus G; Paglialonga F; Pasini A; Printza N; Conti VS; Schmitt CP; Stefanidis C; Verrina E; Vidal E; Webb H; Zampetoglou A; Edefonti A; Holtta T; Shroff R;
    Pediatr Nephrol; 2019 Apr; 34(4):649-655. PubMed ID: 30374605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum β-Trace Protein and β2-Microglobulin as Predictors of ESRD, Mortality, and Cardiovascular Disease in Adults With CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Foster MC; Coresh J; Hsu CY; Xie D; Levey AS; Nelson RG; Eckfeldt JH; Vasan RS; Kimmel PL; Schelling J; Simonson M; Sondheimer JH; Anderson AH; Akkina S; Feldman HI; Kusek JW; Ojo AO; Inker LA;
    Am J Kidney Dis; 2016 Jul; 68(1):68-76. PubMed ID: 26948990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular Disease Risk in Children With Kidney Disease.
    Sethna CB; Merchant K; Reyes A
    Semin Nephrol; 2018 May; 38(3):298-313. PubMed ID: 29753405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.